Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)-Reference-Cited by-同舟云学术

Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU)

Published:2021-11-02 Issue: Volume: Page:1-14
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Severance Randall¹^ORCID,Schwartz Howard²,Dagan Ron³^ORCID,Connor Laurie⁴,Li Jianing⁴,Pedley Alison⁴,Hartzel Jonathan⁴,Sterling Tina M.⁴,Nolan Katrina M.⁴^ORCID,Tamms Gretchen M.⁴,Musey Luwy K.⁴^ORCID,Buchwald Ulrike K.⁴^ORCID

Affiliation:

1. Synexus Clinical Research, Chandler, AZ, USA

2. Research Centers of America, Hollywood, FL, USA

3. Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel

4. Merck & Co., Inc., Kenilworth, NJ, USA

Funder

Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2021.1976581

Reference42 articles.

1. Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report: Streptococcus pneumoniae, 2018. 2018 [accessed 2020 July 23]. https://www.cdc.gov/abcs/reports-findings/survreports/spneu17.html.

2. European Centre for Disease Prevention and Control. Invasive pneumococcal disease. Annual epidemiological report for 2018. 2018 [accessed 2020 Sept 14]. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf.

3. European Centre for Disease Prevention and Control. Seasonal influenza 2018–2019. Annual epidemiological report. 2019 [accessed 2020 Nov 7]. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_seasonal-influenza-corrected.pdf.

4. Update: Influenza Activity in the United States During the 2018–19 Season and Composition of the 2019–20 Influenza Vaccine

5. Burden of four vaccine preventable diseases in older adults

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the efficacy, safety and influencing factors of concomitant and sequential administration of viral respiratory infectious disease vaccines: a systematic review and meta-analysis;Frontiers in Immunology;2023-12-21

2. PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children;Expert Review of Vaccines;2023-12-20

3. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age;Vaccine;2023-10

4. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023;MMWR. Recommendations and Reports;2023-09-08

5. Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making;Vaccines;2023-04-27